X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to investigate the potential of Tonix’s TNX-102 SL, a sublingual formulation of cyclobenzaprine HCl, to reduce the frequency and severity of adverse effects of acute trauma.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-102
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Details:
Funding from the grant will allow to investigate the potential of ACER-801 (osanetant) to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).
Lead Product(s): Osanetant
Therapeutic Area: Psychiatry/Psychology Product Name: ACER-801
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
When treated with entinostat in combination with immunotherapy, two-thirds of mice had a complete disappearance of their tumors and none of the mice had relapse of their tumors when taken off the treatment.
Lead Product(s): Entinostat,Pembrolizumab
Therapeutic Area: Oncology Product Name: MS-275
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
The application of this newly licensed indication will be developed as a novel therapy ("HT-KIT") and shares the same molecular class as the Hoth's current HT-004 drug.
Lead Product(s): HT-KIT
Therapeutic Area: Oncology Product Name: HT-KIT
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2021
Details:
GeneVentiv plans to move the therapy into the clinic mid-2022. The technology, designated as GENV HEM offers a cure for all types of hemophilia patients with or without inhibitors to their missing clotting factors.
Lead Product(s): GENV HEM
Therapeutic Area: Genetic Disease Product Name: GENV HEM
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Geneventiv Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2020
Details:
The study shows that a CRISPR-Cas9-based gene therapy designed to increase the production of ubiquitin protein ligase E3A (UBE3A) — the enzyme lacking in Angelman syndrome — partially or completely corrected physical and behavioral deficits in a mouse model of the disease.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AskBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct deficiency in UBE3A gene.
Lead Product(s): AAV gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AskBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 26, 2020
Details:
The study found that, when used as a prophylactic, EIDD-2801 can prevent severe lung injury in infected mice.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct deficiency in UBE3A gene .
Lead Product(s): Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AskBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
